Get started
Author

Lucas G Orellana

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
2020 · David Adams, Michael Polydefkis, et al. · The Lancet Neurology · 159
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
2025 · David Adams, Jonas Wixner, et al. · JAMA Neurology · 40
PDF
Role of EMSE and STESS scores in the outcome evaluation of status epilepticus
2016 · María Sol Pacha, Lucas Orellana, et al. · Epilepsy & Behavior · 27
Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages
2022 · Roy Freeman, Alejandra Gonzalez‐Duarte, et al. · Annals of Clinical and Translational Neurology · 26
PDF
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
2023 · Laura Obici, Senda Ajroud-Driss, et al. · Neurology and Therapy · 21
PDF
Bases racionales de prescripción para médicos neurólogos
2016 · Lucas Orellana, Alberto Aleman, et al. · Neurología Argentina · 1
Parasympathetic denervation of the heart: an early sign of symptomatic TTR-FAP
2019 · Fabio Barroso, Agustina Badeigts, et al. · Amyloid
Is serum albumin level associated with mortality? Correlation between proteins levels with status epilepticus mortality scoring systems. (P4.231)
2017 · Maria Pacha, Fatima Pantiu, et al. · Neurology
Works count: 8
Citation count: 274
H-index: 5
I10-index: 5
Year
Topic
Type